InflaRx NV (IFRX)
1.56
+0.03
(+1.96%)
USD |
NASDAQ |
Oct 23, 16:00
1.57
+0.01
(+0.64%)
After-Hours: 20:00
InflaRx Enterprise Value : 49.62M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 49.62M |
| October 22, 2026 | 45.20M |
| October 21, 2026 | 48.14M |
| October 20, 2026 | 46.67M |
| October 19, 2026 | 33.41M |
| October 16, 2026 | 14.25M |
| October 15, 2026 | 31.93M |
| October 14, 2026 | 37.83M |
| October 13, 2026 | 48.14M |
| October 12, 2026 | 54.04M |
| October 09, 2026 | 55.51M |
| October 08, 2026 | 45.20M |
| October 07, 2026 | 49.62M |
| October 06, 2026 | 52.56M |
| October 05, 2026 | 67.30M |
| October 02, 2026 | 73.20M |
| October 01, 2026 | 71.72M |
| September 30, 2026 | 84.99M |
| September 29, 2026 | 92.35M |
| September 28, 2026 | 87.93M |
| September 25, 2026 | 98.25M |
| September 24, 2026 | 104.14M |
| September 23, 2026 | 108.56M |
| September 22, 2026 | 126.25M |
| September 21, 2026 | 132.14M |
| Date | Value |
|---|---|
| September 18, 2026 | 127.72M |
| September 17, 2026 | 123.30M |
| September 16, 2026 | 120.35M |
| September 15, 2026 | 117.41M |
| September 14, 2026 | 132.14M |
| September 11, 2026 | 127.72M |
| September 10, 2026 | 121.83M |
| September 09, 2026 | 127.72M |
| September 08, 2026 | 139.51M |
| September 04, 2026 | 146.88M |
| September 03, 2026 | 148.35M |
| September 02, 2026 | 157.20M |
| September 01, 2026 | 138.04M |
| August 31, 2026 | 133.62M |
| August 28, 2026 | 148.35M |
| August 27, 2026 | 154.25M |
| August 26, 2026 | 176.35M |
| August 25, 2026 | 182.25M |
| August 24, 2026 | 121.83M |
| August 21, 2026 | 129.20M |
| August 20, 2026 | 117.41M |
| August 19, 2026 | 132.14M |
| August 18, 2026 | 140.99M |
| August 17, 2026 | 124.78M |
| August 14, 2026 | 120.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| MediGene AG | -- |
| BioNTech SE | 5.602B |
| Immatics NV | 566.19M |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.38M |
| Total Expenses (Quarterly) | 12.38M |
| EPS Diluted (Quarterly) | -0.1052 |
| Earnings Yield | -41.56% |
| Normalized Earnings Yield | -36.39 |